Agios Files for Accelerated Approval of Mitapivat in Sickle Cell Disease

What happened

Agios is seeking FDA accelerated approval for mitapivat in sickle cell disease after its Phase 3 RISE UP trial met the hemoglobin response endpoint (40.6% vs 2.9%) but failed to show significant improvements in pain crises or fatigue. The company plans a confirmatory study to support full approval, gambling that the FDA will accept hemoglobin improvement as a surrogate endpoint for accelerated approval. This filing follows the commercial launch of AQVESME (mitapivat) in thalassemia, which remains constrained by a boxed warning and REMS that add operational friction and have yet to prove scalable patient uptake. With a ~$1.6B market cap and ~$1.26B cash, the enterprise value of ~$0.35B assigns minimal credit to SCD, leaving the stock highly binary on the FDA's decision. The next critical catalyst is the FDA's acceptance of the filing and the subsequent review timeline.

Implication

Over the next 12–18 months, the confirmatory trial results and AQVESME launch metrics will determine whether Agios can become a multi-indication rare-disease company or remain a single-product story with limited upside.

Thesis delta

The thesis now shifts from ‘SCD path uncertain’ to ‘SCD is a live regulatory catalyst with a defined filing strategy.’ The earlier assumption of a Q1 2026 pre-sNDA meeting is replaced by an actual submission, accelerating the timeline and raising the probability of the bull case where hemoglobin response is deemed sufficient for accelerated approval.